Skip to main content

Table 2 Comparison between therapy-related myeloid neoplasm with and without TP53 mutation

From: TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Ā 

Mutated TP53 ( nā€‰ =ā€‰40)

Wild-type TP53 ( nā€‰ =ā€‰68)

p value

Age, years, median (range)

66 (23ā€“87)

68 (18ā€“82)

0.6491*

Male: female

22:18

40:28

0.8405

Prior therapy

Ā Ā Ā 

Ā Chemotherapy only

21

40

0.5518

Ā Radiation only

2

6

0.7082

Ā Combined chemoradiation

17

22

0.2972

Hemoglobin, g/L, median (range)

91 (66ā€“1128)

98 (60ā€“139)

0.1775*

Mean corpuscular volume, median (range)

90 (70ā€“107)

93 (79ā€“116)

0.0076*

White blood cell, Ɨ 109/L, median (range)

3.0 (0.3ā€“41)

3.0 (0.6ā€“93.9)

0.5314*

Absolute neutrophil count, Ɨ 109/L, median (range)

0.8 (0ā€“9.2)

1.1 (0ā€“30.62)

0.2223*

Platelet, Ɨ 109/L, median (range)

32 (5ā€“394)

42 (7ā€“364)

0.0393*

Cytogenetic data

Ā Ā 

<0.0001

Ā Diploid

0

16

Ā 

Ā Non-complex (<3)

3

30

Ā 

Ā Complex (ā‰„3)

36

20

Ā 

Ā Not available

1

2

Ā 

Ā Chromosome 5 aberrations

28

14

<0.0001

Ā Chromosome 7 aberrations

18

23

0.2067

Ā Number of abnormalities, median (range)

7 (1ā€“22)

1 (0ā€“22)

<0.0001*

  1. Asterisk (*) denotes p value was calculated by Mann-Whitney U test. All the others were calculated by Fisherā€™s exact test.